Sutro Biopharma (STRO) Tax Provisions (2022 - 2026)

Sutro Biopharma has reported Tax Provisions for 4 years, with the latest figure at -$88000.0 in Q4 2025.

• Quarterly Tax Provisions fell 103.74% year-over-year to -$88000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.2 million (down 87.63% YoY) and the FY2025 annual result came in at -$99000.0, down 104.19% from the prior year.
• Tax Provisions slipped to -$88000.0 in Q4 2025 per STRO's latest filing, from -$18000.0 in the prior quarter.
• Over five years, Tax Provisions peaked at $15.8 million in Q4 2023 and troughed at -$88000.0 in Q4 2025.
• A 4-year average of $2.6 million and a median of $395000.0 in 2023 frame the typical range for Tax Provisions.
• The sharpest annual moves came in 2024 and 2025: Tax Provisions tumbled 85.11% in 2024, then slumped 325.0% in 2025.
• Over 4 years, Tax Provisions stood at $2.5 million in 2022, then jumped by 532.6% to $15.8 million in 2023, then sank by 85.11% to $2.4 million in 2024, then plunged by 103.74% to -$88000.0 in 2025.
• According to Business Quant data, Tax Provisions over the past three periods registered -$88000.0, -$18000.0, and $2.4 million for Q4 2025, Q2 2025, and Q4 2024 respectively.